Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Public ClinicalTrials.gov record NCT06270082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors
Study identification
- NCT ID
- NCT06270082
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Ikena Oncology
- Industry
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
- IK-595 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2023
- Primary completion
- Sep 7, 2025
- Completion
- Sep 7, 2025
- Last update posted
- Sep 18, 2025
2023 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Sarah Cannon Research Institute at HealthOne | Denver | Colorado | 80218 | — |
| Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center | Washington D.C. | District of Columbia | 20016 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center- Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Next Oncology | Austin | Texas | 78758 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Next Oncology- San Antonio | San Antonio | Texas | 78229 | — |
| INOVA Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06270082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06270082 live on ClinicalTrials.gov.